Usefulness of human telomerase reverse transcriptase in pancreatic juice as a biomarker of pancreatic malignancy

Pancreas

Volumn 38, Issue 5, 2009, Pages 527-533

  Nakashima, Akira ^a   Murakami, Yoshiaki ^a   Uemura, Kenichiro ^a   Hayashidani, Yasuo ^a   Sudo, Takeshi ^a   Hashimoto, Yasushi ^a   Ohge, Hiroki ^a   Oda, Miyo ^b   Sueda, Taijiro ^a   Hiyama, Eiso ^a,c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Human telomerase reverse transcriptase; Immunohistochemistry; Intraductal papillary mucinous neoplasm; Pancreatic ductal adenocarcinoma; Pancreatic juice cytology; Sensitivity and specificity

Indexed keywords

BIOLOGICAL MARKER; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; AGED; ARTICLE; CHRONIC PANCREATITIS; CLINICAL EVALUATION; CYTOLOGY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FEASIBILITY STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS JUICE; PANCREATITIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA, MUCINOUS; ADENOCARCINOMA, PAPILLARY; ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC JUICE; PANCREATIC NEOPLASMS; PREOPERATIVE CARE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 67651100673     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181a16d28     Document Type: Article

References (39)

1. Goodale RL, Gajl-Peczalska K, Dressel T, et al. Cytologic studies for the diagnosis of pancreatic cancer. Cancer. 1981;47:1652-1655.
2. Uehara H, Nakaizumi A, Iishi H, et al. Cytologic examination of pancreatic juice for differential diagnosis of benign and malignant mucin-producing tumors of the pancreas. Cancer. 1994;74:826-833. (Pubitemid 24237461)
3. Nakaizumi A, Tatsuta M, Uehara H, et al. Effectiveness of the cytologic examination of pure pancreatic juice in the diagnosis of early neoplasia of the pancreas. Cancer. 1995;76:750-757.
4. Yamaguchi K, Nakamura M, Shirahane K, et al. Pancreatic juice cytology in IPMN of the pancreas. Pancreatology. 2005;5:416-421, discussion 421. (Pubitemid 41160280)
5. Mitchell ML, Carney CN. Cytologic criteria for the diagnosis of pancreatic carcinoma. Am J Clin Pathol. 1985;83:171-176.
6. Ohuchida K, Mizumoto K, Yamada D, et al. Quantitative analysis of human telomerase reverse transcriptase in pancreatic cancer. Clin Cancer Res. 2006;12:2066-2069.
7. Longnecker DS, Adler G, Hruban RH, et al. Intraductal papillary-mucinous neoplasms of the pancreas. In: Hamilton SR, Aaltonen LA, eds. World Health Organization Classification of Tumours, Pathology and Genetics, Tumours of the Digestive System. Lyon, France: IARC Press; 2000:237-240.
8. Solcia E, Capella C, Kloppel G. Tumors of the pancreas. In: Rosai J, ed. Atlas of Tumor Pathology, 3rd series. Washington, DC: Armed Forces Institute of Pathology; 1997:53-64.
9. Boschman CR, Stryker S, Reddy JK, et al. Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. Am J Pathol. 1994;145:1291-1295. (Pubitemid 24378483)
10. Ishimaru S, Itoh M, Hanada K, et al. Immunocytochemical detection of p53 protein from pancreatic duct brushings in patients with pancreatic carcinoma. Cancer. 1996;77:2233-2239. (Pubitemid 26162414)
11. Tada M, Omata M, Kawai S, et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res. 1993;53:2472-2474. (Pubitemid 23168007)
12. Kondo H, Sugano K, Fukayama N, et al. Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer. 1994;73:1589-1594. (Pubitemid 24085257)
13. Lohr M, Muller P, Mora J, et al. p53 and K-ras mutations in pancreatic juice samples from patients with chronic pancreatitis. Gastrointest Endosc. 2001;53:734-743. (Pubitemid 33717246)
14. Uemura K, Hiyama E, Murakami Y, et al. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours. Oncol Rep. 2003;10:277-283.
15. Hiyama E, Kodama T, Shinbara K, et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res. 1997;57:326-331. (Pubitemid 27036614)
16. Inoue H, Tsuchida A, Kawasaki Y, et al. Preoperative diagnosis of intraductal papillary-mucinous tumors of the pancreas with attention to telomerase activity. Cancer. 2001;91:35-41. (Pubitemid 32052611)
17. Suehara N, Mizumoto K, Tanaka M, et al. Telomerase activity in pancreatic juice differentiates ductal carcinoma from adenoma and pancreatitis. Clin Cancer Res. 1997;3:2479-2483. (Pubitemid 28133171)
18. Uehara H, Nakaizumi A, Tatsuta M, et al. Diagnosis of pancreatic cancer by detecting telomerase activity in pancreatic juice: comparison with K-ras mutations. Am J Gastroenterol. 1999;94: 2513-2518. (Pubitemid 29420682)
19. Myung SJ, Kim MH, Kim YS, et al. Telomerase activity in pure pancreatic juice for the diagnosis of pancreatic cancer may be complementary to K-ras mutation. Gastrointest Endosc. 2000;51:708-713.
20. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997;277:955-959.
21. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science. 1995;269:1236-1241.
22. Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997;90:785-795. (Pubitemid 27357969)
23. Hiyama E, Hiyama K, Yokoyama T, et al. Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues. Neoplasia. 2001;3:17-26. (Pubitemid 32201606)
24. Nakayama J, Tahara H, Tahara E, et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet. 1998;18:65-68. (Pubitemid 28027882)
25. Seki K, Suda T, Aoyagi Y, et al. Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification. Clin Cancer Res. 2001;7: 1976-1981. (Pubitemid 32994834)
26. Gertler R, Rosenberg R, Stricker D, et al. Prognostic potential of the telomerase subunit human telomerase reverse transcriptase in tumor tissue and nontumorous mucosa from patients with colorectal carcinoma. Cancer. 2002;95:2103-2111. (Pubitemid 35253371)
27. Bieche I, Nogues C, Paradis V, et al. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcriptionYpolymerase chain reaction assay. Clin Cancer Res. 2000;6:452-459. (Pubitemid 30111463)
28. Hiyama E, Hiyama K. Telomerase as tumor marker. Cancer Lett. 2003;194:221-233.
29. Yan P, Benhattar J, Seelentag W, et al. Immunohistochemical localization of hTERT protein in human tissues. Histochem Cell Biol. 2004;121:391-397. (Pubitemid 38756936)
30. Hashimoto Y, Murakami Y, Uemura K, et al. Detection of human telomerase reverse transcriptase (hTERT) expression in tissue and pancreatic juice from pancreatic cancer. Surgery. 2008;143:113-125. (Pubitemid 350266038)
31. Kloppel G, Solcia E, Longnecker DS, et al. World Health Organization International Histological Typing of Tumors of the Exocrine Pancreas. Berlin, Germany: Springer; 1996:1-61.
32. Papanicolaou GN. Atlas of Exfoliative Cytology. Cambridge, MA: Harvard University Press; 1963.
33. Elek G, Gyokeres T, Schafer E, et al. Early diagnosis of pancreatobiliary duct malignancies by brush cytology and biopsy. Pathol Oncol Res. 2005;11:145-155. (Pubitemid 41564561)
34. Mackie CR, Cooper MJ, Lewis MH, et al. Non-operative differentiation between pancreatic cancer and chronic pancreatitis. Ann Surg. 1979;189:480-487. (Pubitemid 9172340)
35. Futakawa N, Kimura W, Yamagata S, et al. Significance of K-ras mutation and CEA level in pancreatic juice in the diagnosis of pancreatic cancer. J Hepatobiliary Pancreat Surg. 2000;7:63-71.
36. Yamaguchi T, Shirai Y, Ishihara T, et al. Pancreatic juice cytology in the diagnosis of intraductal papillary mucinous neoplasm of the pancreas: significance of sampling by peroral pancreatoscopy. Cancer. 2005;104:2830-2836. (Pubitemid 41798295)
37. Sai JK, Suyama M, Kubokawa Y, et al. Pancreatic-duct-lavage cytology in candidates for surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas: should the International Consensus Guidelines be revised? Gastrointest Endosc. 2009;69:434-440.
38. Hashimoto Y, Murakami Y, Uemura K, et al. Telomere shortening and telomerase expression during multistage carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas. J Gastrointest Surg. 2008;12:17-28, discussion 28-29.
39. DeWitt J. EUS and pancreatic tumors. In: Hawes RH, Fockens P, eds. Endosonography. London, England: Elsevier; 2006:177-203.